GlassScriptPhysician profile
Paymohn Mahdavi
NPI 1295095669
$1,983.43
in general payments reported to CMS, 2019-2025
21 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.14 · 2020: $63.90 · 2021: $216 · 2022: $688 · 2023: $191 · 2024: $583 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $926.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $473.07 | 2024-2025 | Purified Cortrophin Gel, Iluvien |
| Notal Vision, INC. | $273.54 | 2022 | |
| Novartis Pharmaceuticals Corporation | $199.36 | 2020-2022 | |
| Abbvie INC. | $181.67 | 2022-2023 | |
| Genentech USA, INC. | $136.98 | 2022-2025 | Vabysmo |
| Ivantis, INC | $135.38 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $117.31 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $101.26 | 2022-2025 | Acthar |
| Biogen, INC. | $81.97 | 2022-2023 | |
| Bausch & Lomb Americas INC. | $64.08 | 2022-2024 | Miebo, Xiidra, Vyzulta |
| Eyepoint US, INC. | $41.76 | 2021-2022 | |
| Oyster Point Pharma, INC. | $25.77 | 2024 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $24.68 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.91 | 2019 | |
| Aerie Pharmaceuticals, INC. | $20.88 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $19.23 | 2023 | |
| Kala Pharmaceuticals, INC. | $18.43 | 2020 | |
| Amgen INC. | $17.94 | 2025 | Tepezza |
| Allergan, INC. | $14.81 | 2019 | |
| Thea Pharma INC. | $14.40 | 2025 | Iyuzeh |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paymohn Mahdavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.